Second Sight Medical (EYES) Reports In-Line Q3 EPS

Go back to Second Sight Medical (EYES) Reports In-Line Q3 EPS

Second Sight Reports Third Quarter 2019 Financial Results

November 14, 2019 4:05 PM UTC

-- Reached agreement with FDA regarding the primary efficacy endpoint for the Orion pivotal trial --

LOS ANGELES--(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ: EYES) (Second Sight or the Company), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today reported financial results for the three and nine months ended September 30, 2019.

Recent Corporate Highlights:

Reached agreement with the U.S. Food and Drug Administration (FDA) regarding the primary efficacy... More